The EU and its member states are collectively the world’s largest aid donor, with an annual budget of over $70 billion in 2021. When it comes to global health, however, it has historically punched below its weight. In part, this is due to an internal coordination problem; health is a shared competen...

It’s clear that COVID-19 oral antivirals are effective, and recent deals have made them even cheaper for African countries. But should these countries be investing in these medicines? Or would spending on alternative health services be better value for money? Unfortunately, there is very little avai...

Four new CGD pieces, released today, examine the current state of play on COVID-19 oral antivirals. Our analyses provide a deep-dive in key cross-cutting areas—demand, voluntary licensing deals for generic supply, and deployment—and offer policy actions for 2023 and beyond.

An important debate is taking place in Europe right now on how to fund new antimicrobials. For months it has been speculated that the European Union may move towards implementing transferable exclusivity vouchers (TEVs). In response, 14 Member States wrote to the European Commission outlining why th...

Congress has excellent legislation on the docket that would protect American citizens, yield huge returns, and create a safer, healthier world. We encourage the US Congress to urgently finance and authorize the PASTEUR Act, leveraging American ingenuity to boost our shared health future.

The passing of the Inflation Reduction Act (IRA) could result in nearly $100 billion in savings over a decade, but opponents of value assessment have voiced their concerns. The alternative? External Reference Pricing (ERP).

Antimicrobial resistance is a major global problem. Today, drug resistant infections kill an estimated 1.27 million people per year, and low- and middle-income countries bear the brunt of AMR-related deaths and illness. Changing how we buy antimicrobials can help solve the problem.

Get ready for Pandemic Proof, a new podcast from the Center for Global Development. Hosted by CGD's Amanda Glassman and Javier Guzman and featuring guests from around the world, Pandemic Proof will confront weaknesses in the global architecture for pandemic preparedness and response, and explore pol...

CGD has set up a working group to examine different ways to purchase antimicrobials in LMICs in order to identify actionable policies to improve access and stewardship for key products and increase funding for research into new ones. We are launching today the Working Group’s first working paper.